Question special
Chief Resident

Many patients in our clinical practice receive etomidate for intubation and are thought to potentially be at risk for adrenal insufficiency as a result. Given the decision to exclude this subset of patients from the trial, can we translate or generalize the results to this population? How much of an impact does etomidate have on relative adrenal suppression?